Polycythaemia vera

Stecher, G.; Wolfers, H.; Nettesheim, Paul

doi:10.1055/s-0028-1113017

Search citation statements

Order By: Relevance

Paper Sections

Select...

Radioactive Phosphorus1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

1962

1975

Publication Types

Select...

Article3

Book2

Relationship

Self Cite0

Independent5

Authors

Journals

Cited by 7 publications

(1 citation statement)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several authors [2,22,23] demonstrated the existence of a distinct form of polycythemia vera with an increased risk of developing hematological complications such as leukemia, myeloid metaplasia, myelosclerosis, or marrow aplasia. These complications are most commonly seen in patients exhibiting high initial leukocyte counts and splenic enlargement of at least 2 cm below the costal margin.…”

Section: Radioactive Phosphorusmentioning

confidence: 99%

Present status of32P-therapy in management of polycythemia vera

Meuret

1975

Klin Wochenschr

View full text Add to dashboard Cite

The aim of this study is to assess the present status of 32P-therapy in the management of polycythemia vera. The nature of the disease and its associated clinical problems was considered with respect to the characteristics of the different therapeutic approaches. We concluded that 32P is preferably administered to older patients, especially if long term remissions are achieved, if drugs are taken unreliably, or if patients are difficult to supervise. At present chemotherapy is preferably administered to younger patients, to those who respond inadequately to 32P, or who demonstrate early relapsing hyperproliferation of granulocytopoiesis, or who require 32P-administration at intervals shorter than one year.

show abstract

Section: Radioactive Phosphorusmentioning

confidence: 99%